French and Canadian scientists make discovery that could affect diagnosis, genetic counselling and therapeutic approaches in patients with a rare conditionMontreal – Rare hereditary recessive diseases were thought to be expressed in off-spring only when both parents carry a mutation in the causal gene, but a new study is changing this paradigm. An international research team led by scientists at the University of Lorraine in France along with McGill University and the Research Institute of the McGill University Health Centre (RI-MUHC) in Canada discovered a new cause of a rare condition known as cblC, that they named “epi-cblC”. They reported it in patients from Europe and the United States. Patients who have cblC are not able to process *vitamin B12, leading to severe health problems.cblC is usually caused by two mutations – one inherited from each parent – in a gene called MMACHC. In some patients, the scientists found this disease actually results from a mutation on a single copy of the gene and the silencing of the second copy by a gene modification referred to as epimutation. This epimutation is produced by a mutation in an adjacent gene. Their findings, which were published this month in Nature Communications, may have an impact on diagnosis, and genetic counselling in families with genetic diseases, as well as in the development of new therapeutic approaches.
“We described a distinct and totally new mechanism referred as epi-cblC, whereby an epimutation causes abnormal regulation of the expression of an important vitamin B12 gene. This can result in a serious genetic disease that can cause anemia, neuro-cognitive impairment, and even early death,” says the study’s lead-author, Dr. Jean-Louis Guéant, director of the Inserm unit of Nutrition-Genetics-Environmental Risks at University of Lorraine and head of the Department of Molecular Medicine and Personalized Therapeutics – National Center of Inborn Errors of Metabolism at the University Regional Hospital of Nancy.
cblC is the most common of the inborn genetic errors of vitamin B12 metabolism. Based on one newborn patient case, who died from clinical implications of this disease, the scientists from the University of Lorraine identified an epimutation affecting the MMACHC gene that was present in three generations and in the sperm of the fathers of two of the seven patients. The French and Canadian groups subsequently found it in other cases from Europe and North America and discovered that it resulted from the altered reading of the adjacent gene.
“This epimutation observed in patients causes MMACHC to shut down and become inactive. This has the same effect as an actual mutation in the gene itself. This mechanism may be involved in many more diseases,” explains study’s co-author, Dr. David Rosenblatt, a scientist in the Child Health and Human Development Program at the RI-MUHC and holder of the Dodd Q. Chu and Family Chair in Medical Genetics in the Department of Human Genetics at McGill University.
These results build on a longstanding collaboration between research teams in France and Quebec, along with other collaborators in the United States (New York, Philadelphia, Boston) and Switzerland. In previous work, the researchers at the RI-MUHC and McGill discovered that mutations in the MMACHC gene were responsible for the cblC inborn error of vitamin B12 metabolism. Following the study of several hundred patients, there remained a small number in whom only one mutation could be found in MMACHC.
Geneticists and molecular biologists will now need to look for epimutations in patients who have severe forms of rare diseases despite the lack of mutation in one of the two copies of the gene. The mechanism responsible for epimutation involves the two neighbouring genes of MMACHC, the gene responsible for the disease. Epigenetic mechanisms can also be caused by the environment (diet, stress, exposure to toxic products), and not by the chance of genetic mutations.
“We have identified some 40 rare diseases where this mechanism can be produced at the level of similar trios of genes,” says Dr. Gueant.
“It points out that the study of patients with rare diseases is essential to the advancement of our knowledge of human biology,” adds Dr. Rosenblatt, who is the director of one of the referral laboratories in the world for patients suspected of having this genetic inability to absorb vitamin B12.
*Vitamin B12, or cobalamin (cbl), is essential for healthy functioning of the human nervous system and red blood cell synthesis. Unable to produce the vitamin itself, the human body has to obtain it from animal-based foods such as milk products, eggs, red meat, chicken, fish, and shellfish – or vitamin supplements. Vitamin B12 is not found in vegetables.
About this study
This study was made possible by the financial support of the Region Lorraine, i-SITE Lorraine University of Excellence (LUE), the French National Institute of Health and Medical Research (Inserm) and the Canadian Institutes for Health Research (CIHR).
To access the study published Jan. 04, 2018, in Nature Communications DOI: 10.1038/s41467-017-02306-5
About University of Lorraine
The original University of Nancy was founded in 1572 in the nearby city of Pont-à-Mousson and transferred to Nancy in 1768. The University of Lorraine has been created in 2012 by the merger of the universities of Nancy, the National Polytechnic Institute of Lorraine (INPL) and the University of Metz. The University of Lorraine has over 52,000 students and offers 101 accredited research centers organized in 9 research areas and 8 doctoral colleges. In association with several partners, including Inserm and the Regional University Hospital of Lorraine, the University of Lorraine has recently obtained the I-SITE label from the French call on excellence initiatives for a program called “Lorraine Université d’Excellence” (LUE).
About the Research Institute of the MUHC
The Research Institute of the McGill University Health Centre (RI-MUHC) is a world-renowned biomedical and healthcare research centre. The Institute, which is affiliated with the Faculty of Medicine of McGill University, is the research arm of the McGill University Health Centre (MUHC) – an academic health centre located in Montreal, Canada, that has a mandate to focus on complex care within its community. The RI-MUHC supports over 420 researchers and close to 1,200 research trainees devoted to a broad spectrum of fundamental, clinical and health outcomes research at the Glen and the Montreal General Hospital sites of the MUHC. Its research facilities offer a dynamic multidisciplinary environment that fosters collaboration and leverages discovery aimed at improving the health of individual patients across their lifespan. The RI-MUHC is supported in part by the Fonds de recherche du Québec – Santé (FRQS). http://www.rimuhc.ca
About McGill University
Founded in Montreal, Que., in 1821, McGill is Canada’s leading post-secondary institution. It has two campuses, 11 faculties, 11 professional schools, 300 programs of study and more than 37,000 students, includ-ing 8,300 graduate students. McGill attracts students from over 150 countries around the world, with more than 7,200 international students making up 20 per cent of the student body. Almost half of McGill students claim a first language other than English, including more than 6,200 francophones. http://www.mcgill.ca
About Inserm unit N-GERE
The Institut national de la santé et de la recherche médicale (Inserm) is the French National Institute of Health and Medical Research. It is the only public research institution solely focused on human health and medical research in France. Inserm consists of 339 research units, run by 6,500 permanent staff members. The UMRS Inserm unit on Nutrition-Genetics-Environmental Risks (N-GERE) studies the genetic-metabolic-environmental regulation of development and health. The approach is to unravel the epigenomic-metabolic-epigenetic mechanisms by which environmental exposures and the imbalances/deficiencies in the metabolic network affect very early development and mechanisms of complex and inherited diseases. The unit plays a prominent role in the Fédération Hospitalo-Universitaire (FHU) ARRIMAGE network between local INSERM units, clinical research of the University Regional Hospital Center of Nancy and the national reference centre for inherited metabolic diseases.
Contacts:
Fanny LIENHARDT
Press Relations
Phone: 06-75-04-85-65
Email: fanny.lienhardt@univ-lorraine.fr
Julie ROBERT
Communications Coordinator – Research
McGill University Health Centre
Phone: 1-514-971-4747
Email: julie.robert@muhc.mcgill.ca
Source: McGill University Health Centre
Christine has played an outstanding role in our Lysosomal storage diseases community and for the entire field of rare inherited diseases.
Prof. Maurizio Scarpa was invited to actively participate to the meeting organised by DG Research and Innovation (DG RTD), European Commission, to represent the MetabERN and particularly contributing to the Gastein session “Personalising healthcare: How rare diseases pave the way” that took place on Wednesday 4 October 2017 from 09.00 to 11.00 am.
During the session the different stakeholders discuss about current and future way to exchange knowledge and develop strategies, policies and guidance that pave the way to personalised medicine in Europe, using rare diseases as a model. Advances in genomics and other “omics” technologies have significantly improved our understanding of the pathogenesis of rare diseases. This has opened avenues for piloting new, personalised diagnostic methods and therapies. The impact of “omics” is reinforced by the combination of these data with Real-World Data (RWD).
This meeting was aimed to create collaboration among the Italian HCPs involved in the European Reference Networks (ERN), that as highlighted by Andrzej Jan Rys (Director HelathSystems, Medical Products and Innovation, DG Sante’) are virtual networks of specialists officially born in March 2017, dedicated to the diagnosis and treatment of diseases complex or rare. The 24 ERNs so far approved cover all major disease groups and represent almost a thousand of multidisciplinary medical teams of more than 300 hospitals, located in 25 EU Member States and Norway.
s to establish the first unified European registry that encompasses all inherited metabolic disorders (IMDs) as listed by Orphanet (http://www.orpha.net/). The overall aim of this project is to promote health for children, adolescents and adults affected by rare IMDs and to reduce variation between countries and enable and empower patients, wherever they live, to access the necessary expertise and services and promote research on IMDs and the development of safe and efficacious new treatments. Furthermore, U-IMD will systematically collect data of affected individuals with an IMD of yet unidentified molecular origin and will group them according to their clinical and biochemical phenotype. This will help to identify and systematically treat and follow these patients once the etiology of their disease has been clarified.
Prof Scarpa main key tasks are the following:
24 European Reference Networks (ERNs) were formally launched on 9 March 2017. Representatives from the networks and Member States, along with patients and policymakers, gathered in Vilnius, Lithuania, for the 3rd ERN Conference and kick-off meetings (9 & 10 March).
ERNs. “There is crosslinking in nature,” said Dr Scarpa. “Nothing is isolated.” He said ERNs should be at the frontier of ‘network medicine’ – a new way of thinking of health which breaks down silos between disciplines and disease taxonomies. Tools must be developed to link the ERNs, including a shared virtual counselling system that allowed members of different ERNs to discuss complex cases. “ERNs are not a project or a programme they are a concept – a revolution in the understanding of rare diseases,” he said. “Don’t think of ERNs as discrete networks but as a large task force for sharing expertise.”